Ofatumumab licensed for active relapsing-remitting MS in UK

9 April 2021

Ofatumumab is a disease-modifying therapy (DMT) that works by targeting a type of immune cell called a B cell.  It is the first self-administered B-cell targeting therapy to be licensed in the UK.

After initial guidance from a healthcare professional, ofatumumab can be self-injected at home. The licence is based on the results of two Phase III clinical trials, called ASCLEPIOS, which compared ofatumumab to treatment with another existing DMT, teriflunomide (also called Aubagio).

Ofatumumab demonstrated a significant reduction in the number of relapses as compared to teriflunomide. Read on.

Blog categories: 

Category

Archive